Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes. Researchers at Weill Cornell Medicine, New York-Presbyterian and Memorial Sloan ...
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the ...
Results from Pistoia Alliance’s Lab of the Future survey has shared important findings about the challenges life science companies face. The results from The Pistoia Alliance’s Lab of the Future ...
Researchers at the University of California San Diego have discovered two distinct molecular subtypes of Crohn’s disease by studying organoids derived from adult stem cells in the intestine tissue ...
In this in-depth Q&A, Mutlu Dogruel, Vice President of AI at Cresset shares his insights surrounding chatbots, retrieval augmented generation and AI hallucinations, to open up new possibilities for ...
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade. A combination of treatments in mice with lung cancer have been assessed by scientists ...
In this Q&A, Dr Alan D. Roth, CEO of Oxford Drug Design, explains how his AI drug discovery company, which develops novel molecules for use in cancer treatments, has completed the first in vivo ...
The nasal spray reduced influenza virus levels by >99.99 percent, which could safeguard public health if validated in humans. Scientists at Brigham and Women’s Hospital have developed a spray which ...